A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors.

Abstract

PURPOSE Insulin-like growth factor-1 receptor (IGF-1R) mediates cellular processes in cancer and has been proposed as a therapeutic target. Dalotuzumab (MK-0646) is a humanized IgG1 monoclonal antibody that binds to IGF-1R preventing receptor activation. This study was designed to evaluate the safety and tolerability of dalotuzumab, determine the pharmacokinetic (PK) and pharmacodynamic (PD) profiles, and identify a recommended phase II dose. EXPERIMENTAL DESIGN Patients with tumors expressing IGF-1R protein were allocated to dose-escalating cohorts of three or more patients each and received intravenous dalotuzumab weekly, every 2 or 3 weeks. Plasma was collected for PK analysis. Paired baseline and on-treatment skin and tumor biopsy samples were collected for PD analyses. RESULTS Eighty patients with chemotherapy-refractory solid tumors were enrolled. One dose-limiting toxicity was noted, but a maximum-tolerated dose was not identified. Grade 1 to 3 hyperglycemia, responsive to metformin, occurred in 15 (19%) patients. At dose levels or more than 5 mg/kg, dalotuzumab mean terminal half-life was 95 hours or more, mean C(min) was more than 25 μg/mL, clearance was constant, and serum exposures were approximately dose proportional. Decreases in tumor IGF-1R, downstream receptor signaling, and Ki67 expression were observed. (18)F-Fluorodeoxy-glucose positron emission tomography metabolic responses occurred in three patients. One patient with Ewing's sarcoma showed a mixed radiologic response. The recommended phase II doses were 10, 20, and 30 mg/kg for the weekly, every other week, and every third week schedules, respectively. CONCLUSIONS Dalotuzumab was generally well-tolerated, exhibited dose-proportional PK, inhibited IGF-1R pathway signaling and cell proliferation in treated tumors, and showed clinical activity. The low clearance rate and long terminal half-life support more extended dosing intervals.

DOI: 10.1158/1078-0432.CCR-10-3336
0100200300201220132014201520162017
Citations per Year

719 Citations

Semantic Scholar estimates that this publication has 719 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Atzori2011API, title={A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors.}, author={Francesco Atzori and Josep Tabernero and Andr{\'e}s Cervantes and Ludmila Prudkin and Jordi Andreu and Edith Rodr{\'i}guez-Braun and Amparo Domingo and Jorge Guijarro and Cristina Gamez and Jordi Rodon and Serena Di Cosimo and Holly Brown and Jason Clark and James S Hardwick and Robert A Beckman and William D Hanley and Karl Hsu and Emiliano Calvo and Susana Rosell{\'o} and Ronald B Langdon and Jos{\'e} Baselga}, journal={Clinical cancer research : an official journal of the American Association for Cancer Research}, year={2011}, volume={17 19}, pages={6304-12} }